Statins in the treatment of chronic heart failure: Beyond the hypolipidemic effects
https://doi.org/10.18705/1607-419X-2012-18-1-11-17
Abstract
Despite our knowledge about pathogenesis, clinical characteristics and treatment, chronic heart failure (CHF) remains widespread disease with poor prognosis. However, there is not a common opinion whether statins are reasonable in patients with CHF. The data about efficiency and safety of statins are contradictory and demand evidences due to regular exclusion of patients with CHF from the majority of clinical trials of statins. The reduction of the level of low-density lipoproteins is not the unique mechanism of favourable effect of statins in patients with CHF, therefore, their pleiotropic effects are considered very important.
About the Authors
O. M. Drapkina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
O. N. Korneeva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
L. O. Palatkina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Фомин И.В., Беленков Ю.Н., Мареев В.Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН // Сердечная недостаточность. — 2006. — Т. 7, № 3. — С. 112-115.
2. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения: исследование ЭПОХА-О-ХСН // Сердечная недостаточность. — 2004. — Т. 5, № 1. — С. 4-7.
3. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН, третий пересмотр // Сердечная недостаточность. — 2010. — Т. 11, № 1. — С. 2-62.
4. Endo A. The discovery and development of HMG-CoA reductase inhibitors // J. Lipid Res. — 1992. — Vol. 33, № 11. — P. 1569-1582.
5. Nawrocki J.W., Weiss S.R., Davidson M.N. et al. Reduction of LDL cholesterol by 25 % to 60 % in patients with primary hypercholesterolaemia by atorvastatin, a new HMG-Co-A reductase inhibitor // Arterioscler. Thromb. Vasc. Biol. — 1995. — Vol. 15, № 5. — P. 678-682.
6. van der Harst P., Voors A.A., van Gilst W.H., Böhm M., van Veldhuisen D.J. Statins in the treatment of chronic heart failure: A systematic review // PloS Med. — 2006. — Vol. 3, № 8, e333. — P. 1403-1413.
7. Kannel W.B., Belanger A.J. Epidemiology of heart failure // Am. Heart J. — 1991. — Vol. 121, № 3, Pt. 1. — P. 951-957.
8. Kronmal R.A., Cain K.C., Ye Z., Omenn G.S. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data // Arch. Intern. Med. — 1993. — Vol. 153, № 9. — P. 1065-1073.
9. Rauchhaus M., Clark A.L., Doehner W. et al. The relationship between cholesterol and survival in patients with chronic heart failure // J. Am. Coll. Cardiol. — 2003. — Vol. 42, № 11. — P. 1933-1940.
10. Васюк Ю.А., Школьник Е.Л., Серова М.К., Шупенина Е.Ю., Школьник М.Н. Возможности статинов в патогенетической терапии хронической сердечной недостаточности // Рус. мед. журн. — 2008. — № 4. — С. 205-210.
11. Tonolo G., Ciccarese M., Brizzi P. Plasma lipoprotein and real function during simvastatin treatment // Diabetologia. — 1999. — Vol. 38. — P. 447-451.
12. Rauchhaus M., Koloczek V., Volk H. et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure // Int. J. Cardiol. — 2000. — Vol. 76, № 2-3. — P. 125-133.
13. Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis // Lancet. — 2000. — Vol. 356, № 9233. — Р. 930-933.
14. Sander S., Coleman C.l., Pattel A.A., Kluger J., White C.M. The impact of coenzyme Q10 on systolic function in patient with chronic heart failure // J. Card. Fail. — 2006. — Vol. 12. — P. 464^72.
15. Moosmann B., Behl C. Selenoprotein synthesis and side-effects of statins // Lancet. — 2004. — Vol. 363, № 9412. — P. 892-894.
16. Майрон Д.Дж., Фазио С., Линтон М.Р.Ф. Современные перспективы применения статинов // Междунар. мед. журн. — 2000. — № 6. — С. 28-34.
17. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA Reductase inhibitors // Circulation. — 1998. — Vol. 97, № 2. — P. 1129-1135.
18. Kureishi Y., Luo Z., Shiojima I. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals // Nat. Med. — 2000. — Vol. 6, № 9. — Р. 1004-1009.
19. Ikeda U., Nakagami H., Maeda Y. et al. Coronary artery disease and endothelial nitric oxide synthase and angiotensin-converting enzyme gene polymorphisms // J. Thromb. Thrombolysis. — 1999. — Vol. 8, № 3. — P. 191-195.
20. Лутай М.И. Атеросклероз: современный взгляд на патогенез // Укр. кардиол. журн. — 2004. — № 1. — С. 22-34.
21. Ridker P.M., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for thetargeting of statin therapy in the primary prevention of acute coronary events // N. Engl. J. Med. — 2001. — Vol. 344, № 26. — P. 1959-1965.
22. Ikeda U., Ito T., Shimada K. Statins and C-reactive protein // Lancet. — 1999. — Vol. 353, № 9160. — P. 1274-1275.
23. Атрощенко Е.С. Плейотропные эффекты статинов: новый аспект действия ингибиторов ГМГ-КоА-редуктазы // Мед. новости. — 2004. — № 3. — С. 34-38.
24. Kimura M., Kurose I., Russell J. et al. Effects of fluvastatin on leukocyte-endothelial adhesion in hypercholesterolemic rats // Arterioscler. Thromb. Vasa Biol. — 1997. — Vol. 17, № 8. — P. 1521-1526.
25. Furman C., Copin C., Kandoussi M. at al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability // Atherosclerosis. — 2004. — Vol. 174, № 1. — P. 93-98.
26. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., Ertl G. Improvement of left ventricular remodeling and function by hydroxyl-methylglutaryl-coenzymeА-reductase-inhibition with cerivastatin in rats with heart failure after myocardial infarction // Circulation. — 2001. — Vol. 104, № 9. — P. 982-985.
27. Zaca V., Rastogi S., Imai M. al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure // J. Am. Coll. Cardiol. — 2007. — Vol. 50, № 6. — P. 551-557.
28. Segal R., Pitt B., Poole-Wilson P., Sharma D., Bradstreet D.C., Ikeda L.S. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure // Eur. J. Heart Fail. — 2000. — Vol. 2, suppl. 2. — P. 96.
29. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease // J. Card. Fail. — 1997. — Vol. 3, № 4. — P. 249-254.
30. Mozaffarian D., Nye R., Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure // Am. J. Cardiol. — 2004. — Vol. 93, № 9. — Р. 1124-1129.
31. Hognestad A., Dickstein K., Myhre E., Snapinn S., Kjekshus J. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure // Am. J. Cardiol. — 2004. — Vol. 93, № 5. — P. 603-606.
32. Krum H., Latini R., Maggioni A.P. et al. Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT // Int. J. Cardiol. — 2007. — Vol. 119, № 1. — P. 48-53.
33. Dickinson M.G., Ip J.H., Olshansky B. et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) // Am. Heart J. — 2007. — Vol. 153, № 4. — P. 573-578.
34. Kjekshus J., Dunselman P., Blideskog M. et al. A statin in the treatment of heart failure, controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics // Eur. J. Heart Fail. — 2005. — Vol. 7, № 6. — Р. 1059-1069.
35. Sadek M.M., Haddad T., Haddad H. The role of statins in chronic heart failure // Curr. Opin. Cardiol. — 2009. — Vol. 24, № 2. — Р. 167-171.
36. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial // Lancet. — 2008. — Vol. 372, № 9645. — P. 1231-1239.
Review
For citations:
Drapkina O.M., Korneeva O.N., Palatkina L.O., Ivashkin V.T. Statins in the treatment of chronic heart failure: Beyond the hypolipidemic effects. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(1):11-17. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-1-11-17
Views:
1489
Email this article 